Mind Cure Health Inc (CSE:MCUR, OTCQB:MCURF). President and CEO Kelsey Ramsden talks to Proactive about the Vancouver, Canada-based group's upcoming milestones for 2022 involving its technology and research for psychedelics.
Ramsden talks through progress on its technology platform, as well as its preclinical and clinical initiatives including its synthetic Ibogaine production and its path forward to use MDMA and psychotherapy to treat female sexual hypoactive desire disorder, known as The Desire Project.